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LETTER TO THE EDITORThe Additional Use of Viral
Entry Inhibitors during
Autologous Hematopoietic
Stem Cell Transplantation in
Patients with Non-Hodgkin
Lymphoma and HIV-1
InfectionThe survival of patients infectedwith human immu-
nodeficiency virus type 1 (HIV-1) has considerably
improved since the introduction of antiretroviral ther-
apy (ART). However, therapy is associated with serious
problems, including toxic side effects, and themortality
rate is high among HIV-1-infected patients who are
unable to receive ART or have developed late-stage
acquired immunodeficiency syndrome (AIDS) [1].
ART prevents de novo infection of target cells, and
theoretically, once full suppression of HIV-1 replica-
tion is achieved, viral eradication will occur when all
preexisting cellular reservoirs decay to the point that
no virus is present [2]. In practice, it has not been possi-
ble to eradicateHIV-1 inpatients,mainlybecauseof the
persistence of latently infectedCD41 Tcells, especially
in gut-associated lymphoid tissues [3]. These rare cells
represent only 1 per million CD41 T cells, but their
decay rate is very slow. It has been suggested that
latently infected CD41 T cells have a half-life of about
44 months. HIV-1 eradication would thus take over 60
years of continuous suppressive ART (Figure 1A) [4].CCR5 IN MAINTAINING HIV-1 INFECTION
CC chemokine receptor 5 (CCR5) and CXC che-
mokine receptor 4 (CXCR4) have been identified as
2 major coreceptors for entry of HIV-1 into host cells.
A 32-basepair deletion in the CCR5 allele (CCR5-
delta32) leads to a truncated gene product and provides
resistance againstHIV-1 transmission in individuals ho-
mozygous for thismutation. The decisive role of CCR5
in maintaining HIV infection was substantiated by the
first allogeneic stem cell transplantation (SCT) in an
HIV-1-infected patient from a donor homozygous for
the CCR5-delta32 deletion [5]. Transplantation led to
a change in the patient’s CCR5 allele genotype. Finally,
HIV remains undetectable for more than 2 years after
discontinuing ART, as determined by viral RNA and586proviral DNA PCR assays of peripheral blood (PB),
bone marrow (BM), cerebral fluid, and gut mucosa.
Possible explanations for this finding are: (1) The
conditioning regimen for SCT led to depletion of the
T cell pool and thus significantly reduced the HIV-1
reservoir. (2) Under immunosuppressive treatment,
the absence of activated CD41 T cells abrogated
HIV-1 replication in the remaining T cell fraction.
(3) Repopulating CD41 T cells were resistant to
CCR5-tropic HIV-1 infection because of the absence
of CCR5 surface expression. (4) Reconstitution of the
Tcell poolwas too slow to provide an adequate number
of CD41 target cells for the reemergence of HIV-1
infection via coreceptors other than CCR5.IMPROVING ELIMINATION OF LATENTLY
INFECTED CELLS
Patients with HIV infection have a much higher
risk of developing non-Hodgkin lymphoma than the
general population, and it has been suggested that there
will be a rising demand for intensified antitumor treat-
ment options like SCT [6]. Two prerequisites must be
met to translate our finding of viral control after alloge-
neic SCT into a more feasible and practicable ap-
proach: (1) reduction of HIV-1 infected cells by
T cell depletion, and (2) interference with at least 1 of
the coreceptors on repopulating cells by either phar-
macologic or genetic means. The first prerequisite is
met in patients receiving high-dose chemotherapy
with profound but reversible T cell depletion to treat
malignancies. To fulfill the second prerequisite, entry
inhibitors targeting CCR5 and/or CXCR4 should ad-
ministered in addition to conventional ART during
conditioning regimen in patients receiving SCT, at
least until T cell recovery is completed. Clinical expe-
rience with CCR5 inhibitors has been gained in the
MOTIVATE 1 and 2 trials, where participants receiv-
ingmaraviroc achieved a significant reduction of the vi-
ral load compared to those taking placebo [7]. Gene
therapeutic knock down of HIV entry coreceptors by
modification of hematopoietic stem cells (HSCs) could
provide an effective alternative. In a nonhumanprimate
model, the transduction of anti-CCR5 siRNA into
HSCls led to a stable reduction of CCR5 over a period
of 14 months [8].
In summary,HIV-1 therapy that interfereswith the
entry mechanism seems to be a promising approach
and is still being developed. The procedure just
described may significantly reduce the HIV reservoir
to slow disease progression or shorten the estimated
time required for viral eradication (Figure 1B).
Figure 1. Course of HIV-1 infection. (A) Course of viral load in HIV-1
infection after initiating antiretroviral therapy (ART). After a primary
rapid decline, the decrease in HIV-1 load stagnates because of the long
half-times of latently infected T cells. When HIV-1 RNA levels drop be-
low the detection limit, the viral load dynamics cannot be adequately
predicted. Mathematical algorithms for predicting T cell half-times indi-
cate that HIV-1 eradication cannot be achieved in the course of a lifetime.
(B) T cell depletion, for example during SCT, with additional administra-
tion of HIV-1 entry inhibitors may reduce the number of latently infected
T cells, protect against reinfection, and thus reduce the time to viral
eradication by antiretroviral therapy. [Modified from Sedaghat et al.
PloS Pathog. 2007.]
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